To evaluate in vivo anti-seizure activity of three test compounds in the Scn2aQ54 mouse model of epilepsy caused by a mutation of Scn2a that results in elevated persistent sodium current (Kearney et al, 2001).
|Effective start/end date||12/9/18 → 6/12/20|
- Praxis Precision Medicines, Inc. (Prot #IS00004487)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.